期刊
EXPERT REVIEW OF CARDIOVASCULAR THERAPY
卷 8, 期 8, 页码 1057-1067出版社
TAYLOR & FRANCIS INC
DOI: 10.1586/ERC.10.98
关键词
cardiovascular; diabetes; glucose control; pioglitazone; PPAR-gamma
资金
- AstraZeneca
- Merck Sharp Dohme
- GlaxoSmithKline
- Novartis
- Novo Nordisk
- Pfizer
- Sanofi-Aventis
- Takeda
- Takeda Spain
Pioglitazone is an oral antidiabetic agent that decreases insulin resistance in adipose tissue, liver and muscles. This action is mediated by its link to a nuclear receptor called peroxisome proliferator-activated receptor-gamma. By improving insulin sensitivity, hepatic glucose production decreases and glucose uptake increases in the peripheral tissues. Beyond these effects on glucose metabolism, pioglitazone has positive effects on lipid metabolism, blood pressure, endothelial function, adiponectin and C-reactive protein levels. These make pioglitazone treatment effective beyond glucose control. In this article, current evidence concerning pioglitazone in the treatment of Type 2 diabetes will be reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据